Immunovant Inc
IMVT · NASDAQ
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
ESG Scores
Overall ESG5.4
Environmental6.6
Social4.4
Governance4.5
Gender Diversity
Female Executives0.4519230769230769%
CEO GenderMale
Market Data
Price$39.53-0.39 (-0.98%)
Market Cap—
P/E Ratio—
EPS$—
52W High$—
52W Low$—
Beta—